RonaldTakeshiMitsuyasuMD

Oncology • Los Angeles, CA

Professor of Medicine, David Geffen School of Medicine at UCLA. Director, UCLA CARE Center

Join to view full profile

Dr. Mitsuyasu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mitsuyasu's full profile

Already have an account?

Office
1399 S. Roxbury Drive
Suite 100
Los Angeles, CA 90035
Phone+1 310-557-2273

Fax+1 310-557-3450

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1984
Rush University Medical CenterResidency, Internal Medicine, 1978 - 1981
David Geffen School of Medicine at UCLAClass of 1978

Certifications & Licensure

CA State Medical License 1981 - 2025
IL State Medical License 1979 - 1987
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013-2018
Top Doctors:Southern California Castle Connolly, 2012-2018
America's Top Doctors Castle Connolly, 2010-2018
America's Top Doctors for Cancer Castle Connolly, 2009-2018
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
Completed
Phase 2
Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
Completed
Not Applicable
A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma
Completed
Phase 1
Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
Completed
Phase 2
A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Start of enrollment: 1999 Oct 01
Completed
Phase 3
Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
Completed
Phase 2
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Start of enrollment: 2008 May 14
Completed
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma Start of enrollment: 2010 Jan 22
Completed
Phase 1
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Start of enrollment: 2010 Aug 27
Completed
Phase 1, Phase 2
Autologous Transplant in HIV Patients (BMT CTN 0803) Start of enrollment: 2010 Apr 01
Completed
Phase 2
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Start of enrollment: 2011 Apr 01
Completed
Phase 3
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Start of enrollment: 2011 Jun 28
Completed
Phase 2
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Start of enrollment: 2013 Nov 01
Terminated
Phase 1
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection Start of enrollment: 2013 Apr 01
Completed
Phase 1, Phase 2
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV Start of enrollment: 2013 Dec 04
Completed
Not Applicable
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2015 Oct 21
Recruiting
Phase 1
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Start of enrollment: 2017 Mar 13
Completed
Phase 2
Trial of Ixazomib for Kaposi Sarcoma Start of enrollment: 2023 Nov 07
Recruiting
Phase 2
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas Start of enrollment: 2018 Mar 16
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

479 citations
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
John Scholler, Troy Brady, Gwendolyn Binder-Scholl, Wei-Ting Hwang, Gabriela Plesa
Science Translational Medicine. 2012-05-02
74 citations
Meeting the challenge of hematologic malignancies in sub-Saharan Africa.
Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C. Shea, Peter N. Kazembe
Blood. 2012-05-31
148 citations
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.
Joel M Palefsky, Jeannette Y Lee, Naomi Jay, Stephen E Goldstone, Teresa M Darragh
The New England Journal of Medicine. 2022-06-16

Journal Articles

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies
Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases

Abstracts/Posters

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...
Ronald T. Mitsuyasu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma
Ronald T. Mitsuyasu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

HIV-Infected Patients Less Likely to Get Cancer TreatmentMay 17th, 2016

Grant Support

AIDS Malignancy Clinical Trials Consortium (AMC)National Cancer Institute2010–2012
South American Prevention Of HIV Research Training Program (SAPHIR)National Institute Of Mental Health2011
Ucla-Usc Combined LOS Angeles Core SiteNational Cancer Institute2010–2011
Network Core Research LABNational Cancer Institute2010–2011
AMC Group Chairman, University Of California, LANational Cancer Institute2010–2011
A Prospective Phase II Study Of A High DOSE, Short Course Regimen (R-Codox-M/IvaNational Center For Research Resources2010
A Phase II Trial Of Doxil, Rituximab, Cyclophosphamide, Vincristine, And PrednisNational Center For Research Resources2010
A Phase II Trial Of Combined Modality Therapy PLUS Cetuximab In Hiv-Associated ANational Center For Research Resources2010
Phase IIA Trial Of 1% Topical Cidofovir For Treatment Of High-Grade Perianal SquNational Center For Research Resources2009–2010
A Single Arm, Open-Label Pilot Trial Of The Safety And Immunogenicity Of A QuadrNational Center For Research Resources2009–2010
Short Course Regimen (R-Codox-M/Ivac) INational Center For Research Resources2009
Double-Blind Phase II Study Of Multiple Doses Of Palifermin (RHUKGF) For AIDSNational Center For Research Resources2009
A Phase II Trial Of Doxil, Rituximab, Cyclophosphamide,National Center For Research Resources2009
AIDS Malignancy Clinical Trials ConsortiumNational Cancer Institute2006–2009
A Phase II Trial Of Imatinib Mesylate (GLEEVEC) In Patients With HIV RelatedNational Center For Research Resources2007–2008
AMC 036: A Phase II Trial Of Topical Halofuginone In Patients With HIV RelatNational Center For Research Resources2006–2008
A Phase II Double-Blind, Randomized, Placebo-Controlled Study To Evaluate TheNational Center For Research Resources2006–2008
Recruitment And RetentionNational Cancer Institute2006
Group Chair Administrative Office &Overview Of Entire ApplicationNational Cancer Institute2006
Funding PLAN AdditionsNational Cancer Institute2006
Discretionary FundingNational Cancer Institute2006
Improving Immune Reconstruction With Growth Hormone In Hiv-Infected SubjectsNational Center For Research Resources2005–2006
Randomized Trial Of Standard Chemotherapy With Or Without The Addition Of Ritux)National Center For Research Resources2005
A Randomized Phase I/II Pilot Study Of Intermittent Withdrawal Of AntiretroviNational Center For Research Resources2005
Aids-Associated Malignancies Clinical Trials ConsortiumNational Cancer Institute2003–2005
Rituxan For Treatment Of Hiv-Associated Non-Hodgkin'S LYNational Center For Research Resources2004
Improving Immune Reconstruction With Growth Hormone In Hiv-Infected Subjects...National Center For Research Resources2004
Exploratory, Open-Label, Randomized Trial To EvaluateNational Center For Research Resources2004
AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1994–2003
Phase I Trial Of Antitumor Activity Of Inf AlphaNational Center For Research Resources2001
Phase II Study Of Autologous CD4 Zeta Gene Modified T Cells In HIVNational Center For Research Resources1999–2001
Comparison Study Of Liposomal Doxorubicin To Treat AIDS Kaposi'S SarcomaNational Center For Research Resources1999–2001
Autologous CD4 Zeta Gene Modified T Cells In HIV Infected PatientsNational Center For Research Resources1999–2001
Phase II Study Of The Activity And Safety Of Autologus Cd4-Zeta Gene-ModifiedNational Center For Research Resources1998–2001
Phase II Study Of Intermittent Recombinant Human Interleukin-2 By IntravenouslyNational Center For Research Resources1998–2001
Phase I Trial Of CD34+ Stem Cells Transduced With An HIV RibozymeNational Center For Research Resources1998–2001
Phase III Study Of Indinavir (IDV) With Zidovudine (ZDV) And Lamivudine (3TC)National Center For Research Resources1998–1999
Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Study Of Continuous Infusion Or Subcutaneously Administered ProleukinNational Center For Research Resources1996–1999
Continuous Infusion Proleukin (ALDESLEUKIN) Chiron Recombinant InterleukinNational Center For Research Resources1995–1999
Comparison Study Of Liposomal Doxorubicin With/Without Bleomycin And VincristineNational Center For Research Resources1998
Phase II Study Of Indinavir (IDV) With Zidovudine (ZDV) And Lamivudine (3TC)National Center For Research Resources1997
Open, Non-Comparative Phase II Study Of Topotecan As A Continuous DoseNational Center For Research Resources1996–1997
Combination Vincristine And DDI In AIDS Related Kaposi'S SarcomaNational Center For Research Resources1996–1997
HIV-1 Derived Immunogens In Infected Individuals With >500 CD4 Cells/Cubic MMNational Center For Research Resources1995–1997
Comparison Of Safety And Activity Of HIV-1 Vaccine With PlaceboNational Center For Research Resources1995–1997
AIDS Associated Malignancies Clinical Trials ConsortiumNational Cancer Institute1995–1997
Study Of MN Rgp120/Hiv-1 In HIV Infected Patients With 50-500 C4 Cells/Cubic MMNational Center For Research Resources1995–1996
Monotherapy VS Combination Therapy With Nucleoside Analogs In HIV PatientsNational Center For Research Resources1995–1996
Extended Immunization With MN Rgp120/Hiv-1 VaccineNational Center For Research Resources1995–1996
Dose Escalating Safety And Tolerance Study Of Scd4-Pe40 In HIV PatientsNational Center For Research Resources1995–1996
Safety And Efficacy Of Zidovudine For Asymptomatic HIV Infected PeopleNational Center For Research Resources1995
Phase II Study Of CD8+ T Cells Infused With Recombinant Interleukin-2National Center For Research Resources1995
Combination Vincristine And DDI Or DDC In AIDS Related Kaposi'S SarcomaNational Center For Research Resources1995
Adult AIDS Clinical ResearchNational Institute Of Allergy And Infectious Diseases1994–1995
Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–1993
AIDS Institutional TrainingNational Institute Of Allergy And Infectious Diseases1990–1992
AIDS Clinical Trials Group Conversion From AteuNational Institute Of Allergy And Infectious Diseases1990–1991
Physician-Investigator Development Award ProgramNational Cancer Institute1985–1986
Prevention Of Graft-Vs-Host DiseaseNational Cancer Institute1985